IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) disclosed that on August 27, 2026, its Board Compensation Committee granted non-qualified stock options for an aggregate 62,800 shares of common stock to two newly hired employees under the 2023 Employment Inducement Incentive Award Plan, in line with Nasdaq Listing Rule 5635(c)(4).

The options have a $41.77 exercise price, a 10-year term, and vest over four years: 25% after one year and the remaining 75% in equal monthly installments over the following three years, subject to continued service.

News Explained

The August 27, 2026 grant creates a potential issuance of 62,800 common shares, not an immediate transfer: the two new hires must satisfy the stated vesting and continued-service terms and then exercise the options.

Market Context

The prior inducement-grant event produced a -2.47% 24-hour reaction, while recent collaboration and ...

Analysis

The prior inducement-grant event produced a -2.47% 24-hour reaction, while recent collaboration and earnings announcements produced 2.48% and 2.01% reactions. That record frames this grant as a repeated equity-compensation disclosure; active S-3ASR shelf and net selling remain risks to watch.

Key Figures

Option Grants: 62,800 shares Recipients: two employees Grant Date: August 27, 2026 +5 more

8 metrics

Option Grants 62,800 shares Granted to newly hired employees

Recipients two employees New hires receiving options

Grant Date August 27, 2026 Date options were granted

Exercise Price $41.77 per share Equal to closing price on grant date

Option Term 10-year term Term of stock options

Vesting Period four years Overall vesting schedule

Initial Vesting 25% Vests on the first anniversary

Remaining Vesting 75% Vests in monthly installments over the following three years

Historical Context

5 past events · Latest: Aug 19 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 19	Clinical partnership	Positive	+2.5%	Genentech clinical collaboration to evaluate IDE892 with GDC-7035 in pancreatic cancer
Aug 04	Earnings report	Positive	+2.0%	Second-quarter results, positive OptimUM-02 endpoint, cash balance, and 2030 runway guidance
Jul 31	Inducement grants	Neutral	-2.5%	Prior inducement options granted to fourteen newly hired employees under Nasdaq rule
Jul 27	Clinical trial	Positive	+3.9%	Part 2 monotherapy expansion initiated in IDE892 Phase 1/2 study
Jul 17	Conference presentations	Neutral	+0.2%	ESMO 2026 poster presentations accepted for darovasertib and IDE849 programs

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

IDEAYA's clinical, partnership, and earnings announcements had positive reactions, while the prior inducement-grant disclosure had a negative reaction.

Key Terms

non-qualified stock options, nasdaq listing rule 5635(c)(4)

2 terms

non-qualified stock options financial

"granted non-qualified stock options to purchase an aggregate of 62,800 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August 27, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 62,800 shares of the Company's common stock to two newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individuals' entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $41.77 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer.  Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.  We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications.  Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer 
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302862453.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

What inducement stock options did IDEAYA Biosciences (NASDAQ: IDYA) grant on August 27, 2026?

IDEAYA Biosciences granted non-qualified stock options for an aggregate 62,800 shares on August 27, 2026. According to IDEAYA Biosciences, these options were awarded to two newly hired employees as employment inducement grants under the 2023 Employment Inducement Incentive Award Plan, following Nasdaq Listing Rule 5635(c)(4).

What is the exercise price of the new IDEAYA Biosciences (IDYA) inducement stock options?

The exercise price of the new IDEAYA Biosciences inducement stock options is $41.77 per share. According to IDEAYA Biosciences, this equals the closing price of its common stock on The Nasdaq Global Select Market on the August 27, 2026 grant date for these non-qualified stock options.

How do the IDEAYA Biosciences (IDYA) inducement stock options vest for the new hires?

The IDEAYA Biosciences inducement stock options vest over four years. According to IDEAYA Biosciences, 25% of the options vest on the first anniversary of the vesting commencement date, with the remaining 75% vesting in equal monthly installments over the following three years, subject to continued service.

What is the term of the IDEAYA Biosciences (NASDAQ: IDYA) inducement stock options granted in August 2026?

The IDEAYA Biosciences inducement stock options have a 10-year term from the grant date. According to IDEAYA Biosciences, these non-qualified stock options remain exercisable for ten years, subject to their standard terms and the employees’ continued service on each applicable vesting date.

Under which plan were the August 27, 2026 IDEAYA Biosciences (IDYA) inducement options granted?

The August 27, 2026 IDEAYA Biosciences inducement options were granted under the 2023 Employment Inducement Incentive Award Plan. According to IDEAYA Biosciences, this plan is used exclusively for equity awards to new employees as material inducements to enter employment, consistent with Nasdaq Listing Rule 5635(c)(4).

Who is eligible for equity awards under IDEAYA Biosciences’ 2023 Inducement Plan (IDYA)?

Eligibility under IDEAYA Biosciences’ 2023 Inducement Plan is limited to individuals not previously employed or after a bona fide break. According to IDEAYA Biosciences, the plan is used exclusively for equity awards that serve as material inducements for such individuals to commence employment with the company.